1.Long-acting Somatostatin Analogues.
Journal of Korean Society of Endocrinology 1998;13(3):511-520
No abstract available.
Somatostatin*
2.Somatostatin Receptor.
Eunhee KIM ; Sookjin SOHN ; Mina LEE ; Heesoon PARK ; Jeechang JUNG ; Seungjoon PARK
Journal of Korean Society of Endocrinology 2003;18(4):342-355
No abstract available.
Receptors, Somatostatin*
;
Somatostatin*
3.Antitumor Effects of Somatostatin Analogs in Gastroenteropancreatic Neuroendocrine Tumors.
The Korean Journal of Gastroenterology 2016;68(3):169-171
No abstract available.
Neuroendocrine Tumors*
;
Somatostatin*
4.Preoperative treatment of acromegaly with long-acting somatostatin analog octreotide.
Seok In LEE ; Hyun Kyu KIM ; Kyung Soo KO ; Kyong Soo PARK ; Seong Yeon KIM ; Bo Youn CHO ; Hong Kyu LEE ; Chang Soon KOH ; Hun Ki MIN ; Hyun Jip KIM ; Heu Won JEONG ; Dae Hee HAN
Journal of Korean Society of Endocrinology 1993;8(1):35-41
No abstract available.
Acromegaly*
;
Octreotide*
;
Somatostatin*
5.Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors
Keunyoung KIM ; Seong Jang KIM
Nuclear Medicine and Molecular Imaging 2018;52(3):208-215
Peptide receptor radionuclide therapy (PRRT) is a systemic cytotoxic radiation therapy using a compound of β-emitting radionuclide chelated to a peptide for the treatment of tumor with overexpressed specific cell receptor such as somatostatin receptor subtype 2 (SSTR2) of neuroendocrine tumor (NET). Surgical resection should be performed for the curative treatment for NETs when it is feasible; however, a multi-disciplinary approach is needed when locally advanced or metastasized disease. PRRT with lutetium-177 (Lu-177)-labeled somatostatin analogues, as a new treatment modality targeting metastatic or inoperable NETs expressing the SSTR2, have been developed and successfully used for the past two decades. As Lu-177 emits both β- and γ-radiation, it has the ability as a theragnostic agent for NETs compared with only β-emitting yttrium-90 labeled PRRT. Several recent studies reported that Lu-177 gave an overall positive response and improved the patients' quality of life. To fully exploit its potential, large comparative studies are needed for the assessment of distinct efficacies of Lu-177 labeled PRRT. Additionally, for extending the indications and developing new regimens of Lu-177-based PRRT, more dedicated clinical research is required.
Neuroendocrine Tumors
;
Quality of Life
;
Receptors, Peptide
;
Receptors, Somatostatin
;
Somatostatin
8.Immunohistochemical localization of somatostatin in the midbrain periaqueductal gray of the Korean native goat.
In Se LEE ; Heung Shik LEE ; Seong Joon YI
Korean Journal of Anatomy 1993;26(3):326-337
No abstract available.
Goats*
;
Mesencephalon*
;
Periaqueductal Gray*
;
Somatostatin*
9.Effects of glucose, insulin and somatostatin on collagen production by glomerular mesangial cell.
Chun Gyoo IHM ; Jae Kyung PARK ; Jae Hyung AHN ; Tae Won LEE ; Myung Jae KIM
Korean Journal of Nephrology 1992;11(3):200-206
No abstract available.
Collagen*
;
Glucose*
;
Insulin*
;
Mesangial Cells*
;
Somatostatin*
10.Glucagonoma Syndrome: A case report
Teh Roseleen Nadia Roslan ; Norhayati Yahaya
Journal of the ASEAN Federation of Endocrine Societies 2016;31(1):50-54
A 58-year-old Malay female with underlying diabetes mellitus, presented with chronic skin lesions, associated with weight loss and anemia. There were erosive, scaling skin lesions over the extremities, gluteal region and perioral area. Skin biopsy histopathological examination revealed Necrolytic Migratory Erythema (NME). A CT scan of the abdomen revealed a pancreatic neck and body tumor with possible liver metastases. She was successfully treated with subcutaneous somatostatin and underwent distal pancreatectomy with wedge resection of liver nodule.
Glucagonoma
;
Necrolytic Migratory Erythema
;
Glucagon
;
Somatostatin
Result Analysis
Print
Save
E-mail